logo.jpg
Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen
January 22, 2024 18:40 ET | Genmab A/S
Company Announcement COPENHAGEN, Denmark; January 23, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the appeal arbitrator in its second arbitration arising under its license agreement with...
logo.jpg
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
January 09, 2024 06:45 ET | Genmab A/S
Media Release COPENHAGEN, Denmark; January 9, 2024 TIVDAK sBLA accepted for priority review, FDA action date is May 9, 2024Submission based on positive results from global phase 3 innovaTV 301...
logo.jpg
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
January 03, 2024 00:55 ET | Genmab A/S
Company Announcement COPENHAGEN, Denmark; January 3, 2024 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
logo.jpg
Genmab to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024 09:52 ET | Genmab A/S
Media Release COPENHAGEN, Denmark; January 2, 2024 Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 42nd Annual J.P. Morgan...
logo.jpg
Genmab to Hold 2023 R&D Update and ASH Data Review Meeting
December 12, 2023 07:00 ET | Genmab A/S
Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 12, 2023 – Genmab A/S (Nasdaq: GMAB) will hold its 2023 R&D Update and...
logo.jpg
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
December 09, 2023 12:00 ET | Genmab A/S
Media Release COPENHAGEN, Denmark; December 9, 2023 Data from the pivotal phase 1/2 EPCORE™ NHL-1 study showed 82 percent overall response rate (ORR), 63 percent complete response (CR) and 67...
logo.jpg
Capital Increase in Genmab as a Result of Employee Warrant Exercise
December 05, 2023 17:26 ET | Genmab A/S
Company Announcement COPENHAGEN, Denmark; December 5, 2023 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 7,054 shares as a consequence of the exercise of employee warrants.  The...
logo.jpg
Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
November 27, 2023 07:00 ET | Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; November 27, 2023 U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation (BTD) for epcoritamab-bysp for the treatment of relapsed or...
logo.jpg
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
November 21, 2023 16:45 ET | Genmab A/S
Company Announcement COPENHAGEN, Denmark; November 21, 2023 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
logo.jpg
Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
November 21, 2023 16:42 ET | Genmab A/S
Company Announcement COPENHAGEN, Denmark; November 21, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 10,541 restricted stock units to members of the Board of...